As the life sciences industry continues to experience growth and new scientific and operational opportunities, it also faces several challenges. Looking ahead, life sciences companies will encounter increased competition as the economy recovers. This includes competition for experienced and highly skilled talent, as well as for funding and investor interest across the broader economy. We explore what’s happening and what’s to come for this dynamic industry.
Key takeaways
- For the life sciences ecosystem to continue to thrive, leaders must reevaluate their operating environment and plan for key drivers, including supply chain issues, human capital availability and capital markets.
- Despite the small number of approved drugs, cell and gene therapy companies attract a growing amount and proportion of private investment.
- Virtual trial companies are seeing exponential investment growth spurred by increasing clinical trial durations.
- Additional measures are needed to properly reform the aging medical devices regulatory framework.
Read the outlook for macroeconomic drivers
Read the outlook for biopharma
Read the outlook for life sciences services
